Nirmatrelvir-Ritonavir continues to be recommended for outpatient treatment of COVID-19 infections, especially as cases continue to rise. However, this therapy does present clinical challenges – from drug interactions to off-label dosing and rebound COVID-19 infections, therapy is not as easy as it sounds. Listen as host Geoff Wall describes the clinical challenges and guest Jake Galdo describes the public health considerations for nirmatrelvir-ritonavir use.

The GameChanger 
Nirmatrelvir-ritonavir has significant clinical challenges including various drug interactions with DOACs, statins, amiodarone, and tacrolimus, for example. It’s also important to note that COVID-19 rebound after nirmatrelvir-ritonavir is not due to resistance based on the latest data.

Show Segments 

00:00 – Introductions 
01:25 – Nirmatrelvir-Ritonavir Updates 
04:27 – Nirmatrelvir-Ritonavir Controversy  
06:30 – Drug Interactions  
08:05 – DOACs and Nirmatrelvir-Ritonavir  
11:44 – Statin and Nirmatrelvir-Ritonavir 
13:04 – Amiodarone and Nirmatrelvir-Ritonavir 
15:02 – Tacrolimus and Nirmatrelvir-Ritonavir  
19:33 – COVID-19 Rebound  
23:38 – Equity and Access 
31:44 – Closing Remarks 

Host
Geoff Wall, PharmD, BCPS, FCCP, CGP 
Professor of Pharmacy Practice, Drake University 
Internal Medicine/Critical Care, UnityPoint Health 

Guest
John A. Galdo, PharmD, MBA, BCPS, BCGP (Jake)
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad, Inc

Dr. Galdo have no relevant financial relationships to disclose.

References and Resources

• University of Liverpool Drug Interactions 
• CDC Health Advisory on COVID Rebound Infections
• Paxlovid Patient Eligibility Screening Checklist Tool for Prescriber

Redeem your CPE or CME credit

• CPE (Pharmacist) 
• CME (Physician) 

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode) 

• Pharmacists: Get a Membership
• Prescribers: Get a Membership  

Continuing Education Information

Learning Objectives:
1. Explain common drug interactions associated with Nirmatrelvir-Ritonavir
2. Discuss COVID ‘rebound’ infections
3. Describe public health and healthcare data considerations for Nirmatrelvir-Ritonavir use
 
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-247-H01-P
Initial release date: 07/11/22
Expiration date: 07/11/2023
Additional CPE & CME details can be found here

Follow CEimpact on Social Media:
LinkedIn
Instagram